News | Page 3

Daily news and information for physicians in a range of specialties and practice settings.
Among men who have sex with men, the increased odds of a new HIV infection per HIV-positive partner was reduced by 91% for each partner with whom condoms were always used.
SYMTUZA has been approved by the FDA based on the data of a pair of 48-week pivotal phase 3 trials which showed the non-inferiority safety and efficacy of the drug versus a controlled regimen.
The paradigm of obesity is complex and requires a multi-disciplinary approach, but it is one of the most gratifying experiences for both the physicians and patient when they see the results of weight loss.
Results showed that participants with doctor-diagnosed asthma had a 38% increased risk of developing AF compared to those without asthma.
A probiotic hygiene system resulted in a greater reduction of healthcare-associated infections and surface bacteria than chlorine-based cleansers, including a 66.6% reduction of C. difficile.
Certain lots of the therapy, distributed under the Actavis label in the US, have been detected to have trace amounts of probably human carcinogen NDMA.
The double-blind, placebo-controlled, parallel-group study that aims to observe linaclotide 290 mcg in 600 adult patients with IBS-C in the US.
An examination of trials supporting the 46 therapies approved via the Breakthrough Therapy designation has shown that fewer data supports their approval than what may be believed.
The antiviral treatment for patients at high risk of complications from influenza met the primary objective of efficacy measured by time to improvement of symptoms compared to placebo.
Researchers compared the cost-effectiveness of vancomycin, fidaxomicin, and bezlotoxumab with vancomycin as treatments for treating the first recurrence of Clostridium difficile infection.
Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.